NEWCELX
LIVE

Serial Number

79444171

Owner

KADIMASTEM LTD.

Filing Date

Dec 8, 2025

Add to watchlist:

No watchlists yet
View on USPTO

NEWCELX Trademark

Serial Number: 79444171

NEWCELX is a trademark filed by KADIMASTEM LTD. on December 8, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

KADIMASTEM LTD.

7 Pinhas Sapir Street, P.O.B. 4152

Entity Type: 98

Trademark Details

Filing Date

December 8, 2025

Registration Date

Not Registered

Goods & Services

Research and development services in the field of biotechnology; research and development services in the field of pharmaceutical preparations; research and development services in the field of stem cells; research and development services in the field of cell therapy; research and development of induced pluripotent stem cells; research and development services in the field of pharmaceutical preparations, namely research and development of proprietary cell lines for the treatment of diabetes and ALS; research and development services in the field of pharmaceutical preparations, namely research and development of pluripotent stem cells for the treatment of neurodegenerative and metabolic diseases; scientific research in the medical and pharmaceutical field, and consultancy and information relating thereto; design and development of technology for cell therapy for the treatment of degenerative diseases; pharmaceutical drug development services; development of products for others in the field of pharmaceuticals; scientific services relating to processing human cells; medical and scientific research and development of human stem cells; scientific and technological services in the field of regenerative medicine; scientific and technological services and research and development relating thereto in the field of stem cell-based regenerative therapies for the treatment of neurodegeneration and metabolic disorders; medical and scientific research and development in the field of regenerative medicine; pharmaceutical research and development services in the field of cell regeneration and engineering.

Pharmaceutical preparations for the treatment of degenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of neurodegenerative diseases; pharmaceutical preparations, namely cell therapy for the treatment of metabolic disorders; pharmaceutical preparations, namely cell therapy for the treatment of diabetes and ALS; pharmaceutical preparations for the treatment of central nervous system disorders; pharmaceutical preparations for the treatment of ALS; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of narcolepsy; stem cells for medical purposes; pharmaceutical compositions containing stem cells; pharmaceutical compositions containing stem cells for the treatment of degenerative diseases; pharmaceutical compositions containing stem cells for the treatment of neurodegenerative and metabolic diseases.

Filing History

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 2, 2026 RFCS
REFUSAL PROCESSED BY MPU
Jun 2, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 21, 2026 RFCR
NON-FINAL ACTION WRITTEN
Apr 20, 2026 CNRT
ASSIGNED TO EXAMINER
Apr 10, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 23, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 19, 2026 REPR